IQVIA Holdings ( (IQV) ) has released its Q4 earnings. Here is a breakdown of the information IQVIA Holdings presented to its investors.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
IQVIA Holdings Inc. is a global leader in providing clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries, leveraging advanced technologies and analytics for innovative medical solutions.
IQVIA reported a strong financial performance for the fourth quarter and full year of 2024. The company achieved revenues of $3,958 million in Q4 and $15,405 million for the year. Despite challenges in the clinical research market, IQVIA exceeded its revenue targets, particularly in the Technology & Analytics Solutions segment, and reaffirmed its guidance for 2025.
Key financial metrics include a Q4 GAAP net income of $437 million and an adjusted EBITDA of $996 million. The R&D Solutions sector showed solid bookings, with a contracted backlog of $31.1 billion. The company also reported impressive cash flow figures, with a 41% increase in free cash flow year-over-year, reaching $2,114 million for 2024. Share repurchases amounted to $1.35 billion, with further authorization for buybacks in place.
IQVIA’s outlook for 2025 remains optimistic, with expectations of revenue growth between 4 to 7 percent and an increase in adjusted diluted earnings per share of 5 to 9 percent. The company plans to continue its strategic investments and share repurchase activities, positioning itself strongly for future growth.
